Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib.
10.17998/jlc.2016.16.1.57
- Author:
Dae Ha KIM
1
;
Gee Ho MIN
;
Dong Won LEE
;
Ke Ryun AHN
;
Ji Hye KIM
;
Sang Jun SUH
;
Young Kul JUNG
;
Hyung Joon YIM
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. 93cool@hanmail.net
- Publication Type:Case Report
- Keywords:
Carcinoma, Hepatocellular;
Drug therapy;
Sorafenib;
Treatment outcome
- MeSH:
Carcinoma, Hepatocellular*;
Drug Therapy;
Humans;
Lung*;
Neoplasm Metastasis*;
Phosphotransferases;
Protein-Tyrosine Kinases;
Receptors, Vascular Endothelial Growth Factor;
Treatment Outcome;
Venous Thrombosis
- From:Journal of Liver Cancer
2016;16(1):57-62
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.
